Search Results - "Burri RJ"

Protective role of TGF-β1 (-509C>T, rs1800469) single-nucleotide polymorphism against radiation toxicities in locally advanced head and neck cancer.

Authors: Krishnan, M. P. Sarath Goyal, Bela Gupta, Sweety et al.

Source: Indian Journal of Pathology & Microbiology. Jan-Mar2026, Vol. 69 Issue 1, p23-28. 6p.

Impact of androgen deprivation therapy in patients with unfavorable intermediate-risk prostate cancer receiving brachytherapy-based dose-escalated radiation therapy.

Authors: Sebastian, Nikhil T. Goyal, Subir Liu, Yuan et al.

Source: Journal of Contemporary Brachytherapy. 2024, Vol. 16 Issue 4, p268-272. 5p.

Prostate cancer with nodular bladder invasion (stage T4N1) cured by low-dose-rate brachytherapy with seminal vesicle implantation in combination with external beam radiotherapy of biologically effective dose ≥ 220 Gy: a case report.

Authors: Keisei Okamoto¹ keiseiok814@gmail.com

Source: Journal of Contemporary Brachytherapy. 2021, Vol. 13 Issue 1, p91-94. 4p.

The pons as an optimal background reference region for spinal ¹⁸F-FET PET/MRI evaluation.

Authors: Huang, Jing Wang, Jiyuan Cui, Bixiao et al.

Source: EJNMMI Research. 7/26/2024, Vol. 14 Issue 1, p1-10. 10p.

F‐SHARP: a Phase I/II trial of focal salvage high‐dose‐rate brachytherapy for Radiorecurrent prostate cancer.

Authors: Solanki, Abhishek A. Yoo, Ryan K. Adams, William et al.

Source: BJU International. Feb2024, Vol. 133 Issue 2, p188-196. 9p.

Salvage low‐dose vs high‐dose brachytherapy for radio‐recurrent prostate cancer.

Authors: Xie, Shaoqin Liu, Jianjiang Shen, Bin et al.

Source: BJU International. Jun2025, Vol. 135 Issue 6, p940-952. 13p.

Dosimetric Comparison of Tangential Beam and Equally Spaced Beam Intensity-modulated Radiation Therapy in Right Breast Cancer Following Breast-conserving Surgery: A Retrospective Study.

Authors: Rajadurai, E Kumar, A Saravana Govindarajan, KN et al.

Source: Journal of Medical Physics. Apr-Jun2025, Vol. 50 Issue 2, p320-328. 9p.

Association of polymorphisms in TGFB1, XRCC1, XRCC3 genes and CD8 T-lymphocyte apoptosis with adverse effect of radiotherapy for prostate cancer.

Authors: Mališić, Emina Petrović, Nina Brengues, Muriel et al.

Source: Scientific Reports. 12/9/2022, Vol. 12 Issue 1, p1-13. 13p.

Comparative evaluation of machine learning models in predicting overall survival for nasopharyngeal carcinoma using ¹⁸F-FDG PET-CT parameters.

Authors: Lin D Wu W Huang Z et al.

Source: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2025 Apr; Vol. 27 (4), pp. 1748-1759. Date of Electronic Publication: 2024 Sep 20.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Springer Italia Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE

Anatomy-dependent lung doses from 3D-conformal breast-cancer radiotherapy.

Authors: Kundrát, Pavel Rennau, Hannes Remmele, Julia et al.

Source: Scientific Reports. 6/29/2022, Vol. 12 Issue 1, p1-9. 9p.

The survival outcomes of very young and elderly patients with high-risk prostate cancer after radical treatments: A population-matched study.

Authors: Ma, Kai Song, Pan Qing, Yuxin et al.

Source: Journal of Cancer Research & Therapeutics. Apr2022, Vol. 18 Issue 2, p391-398. 8p.

Evolution of Nutritional Status in Patients with Advanced Head and Neck Cancer Undergoing Surgical Treatment or Organ Preservation Protocol.

Authors: Silva, Naira Marceli Fraga Carvalho, Ingrid Roberta de Azevedo Lopes, Lilian Pinheiro et al.

Source: Nutrition & Cancer. 2022, Vol. 74 Issue 3, p852-859. 8p. 6 Charts.

Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017.

Authors: Aljubran, Ali Abusamra, Ashraf Alkhateeb, Sultan et al.

Source: Urology Annals. Apr-Jun2018, Vol. 10 Issue 2, p138-145. 8p.

Focal salvage low‐dose‐rate brachytherapy for recurrent prostate cancer based on magnetic resonance imaging/transrectal ultrasound fusion biopsy technique.

Authors: Yamada, Yasuhiro Okihara, Koji Masui, Koji et al.

Source: International Journal of Urology. Feb2020, Vol. 27 Issue 2, p149-155. 7p.

Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Authors: Abusamra, Ashraf Murshid, Esam Kushi, Hussain et al.

Source: Urology Annals. Apr-Jun2016, Vol. 8 Issue 2, p123-130. 8p.

Impact of age on the Quadrella index assessing oncological and functional results after prostate brachytherapy: A 6-year analysis.

Authors: Tremblay, Guillaume Truong An Nguyen Marolleau, Julien et al.

Source: Journal of Contemporary Brachytherapy. 2023, Vol. 15 Issue 2, p89-95. 7p.

Association between single nucleotide polymorphisms in DNA repair genes and the efficacy of radiotherapy in nasopharyngeal carcinoma patients.

Authors: Benzeid, Rajaa Gihbid, Amin Tawfik, Nezha et al.

Source: Contemporary Oncology / Współczesna Onkologia. 2023, Vol. 27 Issue 1, p28-34. 7p.

Lifetime cost-effectiveness analysis of intraoperative radiation therapy versus external beam radiation therapy for early stage breast cancer.

Authors: Patel, Rakesh Ivanov, Olga Voigt, Jeff

Source: Cost Effectiveness & Resource Allocation. 11/9/2017, Vol. 15, p1-12. 12p. 1 Diagram, 3 Charts, 7 Graphs.

Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostatespecific antigen kinetics, and cancer control.

Authors: Mayrata, Esther Espinosa, Jose Maria Büchser, David et al.

Source: Journal of Contemporary Brachytherapy. 2021, Vol. 13 Issue 1, p12-17. 6p.

Riding the tiger – physiological and pathological effects of superoxide and hydrogen peroxide generated in the mitochondrial matrix.

Authors: Brand, Martin D.¹ (AUTHOR)

Source: Critical Reviews in Biochemistry & Molecular Biology. Dec2020, Vol. 55 Issue 6, p592-661. 70p.